OncLive’s educational meeting on the gaps in lung cancer care, decoded by KOL Pulse. Across both days: small cell lung cancer — tarlatamab as the 2L standard, DLL3-directed T-cell engagers, and emerging ADCs; EGFR-mutant NSCLC — how to choose 1L combinations and treat early-stage disease; and, on Day 2, perioperative / resectable NSCLC (CheckMate-77T by nodal status, management after neoadjuvant therapy) and oligometastatic NSCLC radiotherapy. Below: the presenters’ data slides, transcribed with sources.
The physician faculty presenting at BTG Lung 2026. X handles are linked where confirmed; other names are listed as presented.
Every card below is a data slide presented at BTG Lung 2026, transcribed by KOL Pulse with its primary-source citation. Where a slide maps to a tracked trial, a deep-link to the full KOL Pulse trial profile is provided.
Tarlatamab vs chemotherapy, 2L SCLC. OS HR 0.60 (p<0.001); mOS 13.6 mo (95% CI 11.1-NR) vs 8.3 mo (7.0-10.2). ORR 35% (29-41) vs 20% (16-26). mDoR 6.9 vs 5.5 mo. Grade >=3 TRAEs 27% vs 62%; TRAE-related discontinuation 3% vs 6%. n=254 vs 255.
Ifinatamab deruxtecan (B7-H3) — IDeate-Lung01, Ph2: ORR 48%, mPFS 4.9, mOS 10.3. Sacituzumab govitecan (TROP2) — TROPiCS-03, Ph2: ORR 42%, mPFS 4.4, mOS 13.6. ABBV-706 (SEZ6) — NCT05599984, Ph1: ORR 52%, mPFS 5.4, mOS 11.3. Zocilurtatug pelitecan (DLL3) — NCT06179069, Ph1: ORR 47%, mPFS 5.4.
SoC = platinum/etoposide/ICI (60-70% RR). Additive: BiTE (obrixtamig DAREON-Lung-1; tarlatamab DeLLphi-312), VEGFi (ivonescimab PD-L1xVEGF; BNT327 PD-L1xVEGF; PF-08634404 PD-1xVEGF), other (BMS-986489 anti-fucosyl-GM1 + nivolumab). Replacement: +/- carboplatin; I-DXd OR ABBV-706 OR ZL-1310 (IDeate-Lung03/SEZanne); atezolizumab.
Earlier use/maintenance: tarlatamab maintenance (DeLLphi-303/305), frontline induction+maintenance (DeLLphi-312). 2L+: tarlatamab (DeLLphi-304, established OS benefit) or ADCs/chemo/lurbinectedin or DLL3 TCE later line. Rational combos: PD-L1 blockade, ADCs (B7-H3/SEZ6/TROP2), radiation, biomarker-selected (DLL3 expression, CTC-DLL3).
Classical (exon19 del ~45%, L858R ~35%, L861Q): osimertinib [FLAURA]; lazertinib + amivantamab SC [MARIPOSA] (ECOG PS 0-1, anticoag-eligible); osimertinib + carboplatin/pemetrexed [FLAURA2] (adequate renal fn). PACC (G719X, S768I): afatinib. Exon20 insertion (~10%): sunvozertinib or amivantamab + carbo/pem.
Central controversy: which patients benefit most from combination therapies vs EGFR-TKI monotherapy? And: chemotherapy + osimertinib [FLAURA2] versus amivantamab + lazertinib [MARIPOSA] — how to select, and how to manage toxicities.
Central question: how to individualize curative-intent EGFR therapy (who/when/what/how long/what next). Domains: intent & duration (3 vs 5 vs indefinite osimertinib); timing/perioperative (neoadjuvant vs adjuvant vs true perioperative); chemo de-escalation; risk & MRD (ctDNA-guided); recurrence & next therapy (osi rechallenge). Evidence: ADAURA (Wu, NEJM 2020), NeoADAURA (He, JCO 2025), ADAURA2 (NCT05120349), TARGET (NCT05526755), CTONG2105 (NCT05536505).
pCR rate, nivolumab vs placebo. Stage III N2: 22.0% vs 5.6% (diff 16.4%); with resection 28.6% vs 7.6% (diff 21.0%). Stage III non-N2: 25.5% vs 5.3% (diff 20.2%); with resection 31.1% vs 6.7% (diff 24.4%). Single-station N2: 18.6% vs 7.5% (diff 11.1%). Multistation N2: 29.0% vs 2.7% (diff 26.3%); with resection 37.5% vs 3.4% (diff 34.1%). Biology (nodal burden) does not blunt perioperative benefit.
Is the adjuvant IO component necessary? Pathologic response, resection margins, and ctDNA may inform adjuvant decisions (needs agreed standards). Oncogene-addicted (AGA): neoadjuvant TKI data are less robust than chemo+IO; adjuvant duration in the perioperative setting may be informed by ADAURA, ARTS, ALINA, ELEVATE; decisions may be guided by ctDNA. Surveillance: risk-stratified by stage / residual viable tumor / ctDNA / driver; tools include MRI brain + ctDNA; metastasis-directed therapy adds value.
1. Think biology > anatomy. 2. Systemic therapy first. 3. “Unresectable” should be a multidisciplinary discussion, not a reflex. CheckMate-77T shows biology (single- vs multistation N2) does not determine benefit.
Top 5 questions shaping the role of RT in oligometastatic NSCLC: 1. Who? 2. When? 3. Where? 4. How much? 5. Which biology? Metastasis-directed therapy plus better systemic options raise the value of local therapy.
The physician and media voices driving the BTG Lung 2026 discussion on X. Verbatim posts, ranked by reach.
The pivotal trials anchoring the BTG Lung 2026 discussion — each links to its full KOL Pulse trial profile with sentiment, slides, and engagement data.
Tarlatamab (DLL3 BiTE) vs chemo in 2L SCLC — the established 2L standard-of-care voice at BTG Lung 2026.
View trial profile →Amivantamab + lazertinib vs osimertinib in 1L EGFR-mutant NSCLC — one side of the FLAURA2-vs-MARIPOSA 1L combo debate.
View trial profile →Osimertinib + chemotherapy vs osimertinib in 1L EGFR-mutant NSCLC — the chemo-combination arm of the 1L controversy.
View trial profile →Osimertinib monotherapy in 1L EGFR-mutant NSCLC — the TKI-monotherapy benchmark referenced in the 1L decision framework.
View trial profile →Adjuvant osimertinib in resected EGFR-mutant NSCLC — anchor of the early-stage EGFR treatment-map discussion.
View trial profile →Perioperative nivolumab in resectable NSCLC — the Day-2 pCR-by-nodal-status analysis showing benefit holds across single- and multistation N2 disease.
View trial profile →Adjuvant alectinib in resected ALK-positive NSCLC — referenced in the Day-2 discussion of adjuvant duration after neoadjuvant therapy.
View trial profile →